和誉医药首个自研创新药获批；Agios首创疗法再获FDA批准；阿斯利康自免“迷你双抗”在华申报上市

药财社2025-12-25

●药闻快报▲关注药财社聚焦医药界▲1和誉医药首个自研创新药获批近日，国家药监局（NMPA）官网显示，张江药谷企业和誉医药自主研发的CSF-1R高选择性小分子抑制剂匹米替尼（pimicotinib）获批上市，用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤（TGCT）患者。据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤（TGCT...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594225778?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-25 19:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2594225778","market":"us","top_or_hot":-1,"title":"和誉医药首个自研创新药获批；Agios首创疗法再获FDA批准；阿斯利康自免“迷你双抗”在华申报上市","media":"药财社","content":"<div>\n<p>●药闻快报▲关注药财社聚焦医药界▲1和誉医药首个自研创新药获批近日，国家药监局（NMPA）官网显示，张江药谷企业和誉医药自主研发的CSF-1R高选择性小分子抑制剂匹米替尼（pimicotinib）获批上市，用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤（TGCT）患者。据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤（TGCT...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和誉医药首个自研创新药获批；Agios首创疗法再获FDA批准；阿斯利康自免“迷你双抗”在华申报上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和誉医药首个自研创新药获批；Agios首创疗法再获FDA批准；阿斯利康自免“迷你双抗”在华申报上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 19:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b><strong>药财社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>●药闻快报▲关注药财社聚焦医药界▲1和誉医药首个自研创新药获批近日，国家药监局（NMPA）官网显示，张江药谷企业和誉医药自主研发的CSF-1R高选择性小分子抑制剂匹米替尼（pimicotinib）获批上市，用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤（TGCT）患者。据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤（TGCT...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛欧洲核心股票组合Acc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b","article_id":"2594225778","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594225778","pubTimestamp":1766660515,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤系统性治疗药物。2Agios首创疗法再获FDA批准Agios Pharmaceuticals近日宣布，美国FDA已批准口服丙酮酸激酶激活剂Aqvesme用于治疗α型或β型地中海贫血成年患者。根据新闻稿，mitapivat为首款同时获FDA批准用于治疗非输血依赖型和输血依赖型α或β地中海贫血的药物。3阿斯利康自免“迷你双抗”在华申报上市12月24日，CDE网站显示，阿斯利康的戈鲁利单抗在华申报上市。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","BK4588":"碎股","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC"},"translate_title":"Heyu Pharmaceutical's first self-developed innovative drug was approved; Agios's first therapy was approved by the FDA again; AstraZeneca's self-immune \"mini dual antibody\" applies for listing in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.5},"content_text":"●药闻快报▲关注药财社聚焦医药界▲1和誉医药首个自研创新药获批近日，国家药监局（NMPA）官网显示，张江药谷企业和誉医药自主研发的CSF-1R高选择性小分子抑制剂匹米替尼（pimicotinib）获批上市，用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤（TGCT）患者。据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤（TGCT）系统性治疗药物。TGCT既往又称色素沉着绒毛结节性滑膜炎（PVNS），是一种罕见的局部侵袭性肿瘤，可导致受累关节出现进行性加重的肿胀、僵硬及活动功能受限，严重影响患者的日常活动能力和生活质量。若不进行治疗或病情复发，可能对骨骼、关节及周围组织造成不可逆损伤。2Agios首创疗法再获FDA批准Agios Pharmaceuticals近日宣布，美国FDA已批准口服丙酮酸激酶（PK）激活剂Aqvesme（mitapivat）用于治疗α型或β型地中海贫血成年患者。根据新闻稿，mitapivat为首款同时获FDA批准用于治疗非输血依赖型和输血依赖型α或β地中海贫血的药物。此次mitapivat在地中海贫血领域的获批是基于全球多中心、随机、双盲、安慰剂对照的3期ENERGIZE和ENERGIZE-T研究结果，分别针对非输血依赖型和输血依赖型成年α或β地中海贫血患者开展，共纳入452例具有真实世界代表性的患者。研究结果显示，两项3期试验均达到了所有主要和关键次要终点，与安慰剂相比，mitapivat在改善溶血性贫血和关键生活质量指标方面具有显著获益，包括明显降低输血负担，以及显著提升血红蛋白水平并减轻疲劳症状。Mitapivat是一款“first-in-class”的口服丙酮酸激酶激活剂，它能改善红细胞的能量供应，提高红细胞的健康水平。2022年2月，美国FDA批准了mitapivat（商品名Pyrukynd）上市，它成为针对丙酮酸激酶缺乏症的首个疾病修正疗法。3阿斯利康自免“迷你双抗”在华申报上市12月24日，CDE网站显示，阿斯利康的戈鲁利单抗（gefurulimab）在华申报上市。根据临床试验进展，推测此次申报的适应症为全身型重症肌无力（gMG）。戈鲁利单抗是一种迷你双抗（25kD），只包含了靶向C5的抗体重链可变区和与白蛋白（Albumin）特异性结合的抗体片段。较小的分子量可以带来更好的渗透性，并且与白蛋白的结合能够延长其半衰期。全身型重症肌无力（gMG）是一种罕见、使人衰弱、慢性的自身免疫性神经肌肉疾病，会导致肌肉功能丧失和严重无力。gMG患者最初可能出现言语不清、复视、眼睑下垂和无力等症状，随着疾病进展，症状会变得更加严重，包括极度疲劳、吞咽困难、窒息和呼吸衰竭。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594225778","isCrawlerRequest":true}